Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Dec 20;132(24):3003-3005.
doi: 10.1097/CM9.0000000000000556.

Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion

Cun-Liang Cai  1 , Ming-Qiang Zhang, Jun Guo, Li-Wan Wang, Jing-Quan Zhao, Wen-Jia Guo, Xiang-Dong Mu
Affiliations
Comment

Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion

Cun-Liang Cai et al. Chin Med J (Engl). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
CT and histopathological findings. (A–C) Chest CT before treatment. (A) An 18 mm × 15 mm irregular mass in the apical segment of the right upper lobe with pleura invasion, as indicated by the arrow. (B) Massive right pleura effusion. (C) Metastasis of the left adrenal gland, as indicated by the arrow. (D and E) Histopathological findings of tissue biopsy. The tumor contains mostly diffuse proliferated spindle-shaped tumor cells with partial necrosis and scattered infiltration of lymphocytes. HE staining, original magnification ×100 and HE original magnification ×200, respectively. (F) Spindle-shaped tumor cells were found in the paraffin section of the pleural effusion cell collections, HE staining, original magnification ×200. (G–I) Chest CT findings at the 4-month follow-up after crizotinib treatment. (G) Lung lesions shrank. (H) The pleura effusion nearly vanished. (I) the metastasis of the left adrenal gland eliminated. CT: Computed tomography; HE: Hematoxylin and eosin.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Weissferdt A. Pulmonary sarcomatoid carcinomas: a review. Adv Anat Pathol 2018; 25:304–313.. doi: 10.1097/PAP.0000000000000202. - PubMed
    1. Lee S, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, et al. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 2011; 137:1203–1211.. doi: 10.1007/s00432-011-0986-0. - PMC - PubMed
    1. Sgambato A, Casaluce F, Maione P, Gridelli C. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther 2018; 18:71–80.. doi: 10.1080/14737140.2018.1412260. - PubMed
    1. Choi HS, Yim SH, Xu HD, Jung SH, Shin SH, Hu HJ, et al. Tropomyosin3 overexpression and a potential link to epithelial-mesenchymal transition in human hepatocellular carcinoma. BMC Cancer 2010; 10:122–133.. doi: 10.1186/1471-2407-10-122. - PMC - PubMed
    1. Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2015; 29:E5381–E5390.. doi: 10.1073/pnas.1515281112. - PMC - PubMed